Sulfasalazine

Proctitis, Colitis, Ulcerative, Arthritis, Juvenile + 4 more
Treatment
20 Active Studies for Sulfasalazine

What is Sulfasalazine

SulfasalazineThe Generic name of this drug
Treatment SummarySulfasalazine is a medication used to treat inflammatory bowel diseases. It works by breaking down in the colon to form 5-aminosalicylic acid, which helps reduce inflammation in the intestines.
Azulfidineis the brand name
image of different drug pills on a surface
Sulfasalazine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Azulfidine
Sulfasalazine
1950
38

Effectiveness

How Sulfasalazine Affects PatientsThe way sulfasalazine works is not yet understood, but it may help reduce inflammation and alter the immune system. It is known to reach high concentrations in the liver, serous fluids, and intestines. In patients with ulcerative colitis, it appears that the 5-aminosalicylic acid component is responsible for the therapeutic effect. For those with rheumatoid arthritis, the contribution of sulfasalazine and its metabolites to treatment is currently unknown.
How Sulfasalazine works in the bodySulfasalazine works in the body to reduce inflammation. It does this by blocking certain molecules like leukotrienes and prostaglandins that cause inflammation. It also stops enzymes like phospholipase A2, COX-1 and COX-2, and arachidonate 5-lipoxygenase from working. This stops the inflammation in the body.

When to interrupt dosage

The measure of Sulfasalazine is contingent upon the diagnosed malady, including moderate Ulcerative colitis, Rheumatoid Arthritis and Ulcerative Colitis. The sum of dosage alters as per the delivery process (e.g. Tablet or Enema - Rectal) noted in the table beneath.
Condition
Dosage
Administration
Arthritis, Juvenile
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Proctitis
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Colitis, Ulcerative
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Ulcerative Colitis
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Rheumatoid Arthritis
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Crohn's Disease
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral
Ulcerative Colitis
, 500.0 mg, 30.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Suspension, Rectal, Suspension - Rectal, Enema, Enema - Rectal, Suppository - Rectal, Tablet, film coated, Tablet, film coated - Oral

Warnings

Sulfasalazine has seven known counter-indications, so it should be avoided in the event of any of the conditions laid out in the accompanying table.Sulfasalazine Contraindications
Condition
Risk Level
Notes
Porphyrias
Do Not Combine
Intestines
Do Not Combine
There are 20 known major drug interactions with Sulfasalazine.
Common Sulfasalazine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acteoside.
Sulfasalazine Toxicity & Overdose RiskStudies on animals have found that sulfasalazine is linked to an increased risk of bladder and kidney tumors in rats, and liver tumors in mice. It has also been linked to fertility problems in male rats, and there are reports of neural tube defects in infants born to mothers who took the drug while pregnant. There have been no studies on pregnant humans but a survey suggests that there is no increase in fetal complications compared to the general population. It is not known how sulfasalazine may affect the growth and development of children exposed to the drug during pregnancy.
image of a doctor in a lab doing drug, clinical research

Sulfasalazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Sulfasalazine?

114 active studies are currently being conducted to investigate the effectiveness of Sulfasalazine in providing relief from Polyarticular juvenile rheumatoid arthritis, chronic or unspecified Ulcerative Colitis and Crohn's Disease.
Condition
Clinical Trials
Trial Phases
Colitis, Ulcerative
0 Actively Recruiting
Proctitis
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Rheumatoid Arthritis
54 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Crohn's Disease
54 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Arthritis, Juvenile
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting

Sulfasalazine Reviews: What are patients saying about Sulfasalazine?

5Patient Review
6/26/2017
Sulfasalazine for Ulcerative Colitis currently Without Symptoms
Sulfasalazine has been incredibly effective in treating my Colitis flare-ups. I start seeing results within two weeks, and haven't had any issues for the past two months.
4Patient Review
6/22/2017
Sulfasalazine for Collagenous Colitis
I've been using this treatment for a couple years now, and it's made a big difference (I use it three times per day). It's also much cheaper than budesonide.
3Patient Review
5/5/2019
Sulfasalazine for Rheumatic Disease causing Pain & Stiffness in Backbone
I developed a skin rash after using this treatment.
2.7Patient Review
4/16/2019
Sulfasalazine for Rheumatoid Arthritis
Though my pain has decreased significantly, I now feel incredibly exhausted all the time. It's like I just ran a marathon. Has anyone else experienced this?
2Patient Review
9/7/2017
Sulfasalazine for Rheumatoid Arthritis
I've only just started taking this medication.
2Patient Review
10/11/2022
Sulfasalazine for Rheumatoid Arthritis
I've been using this medication for about a month to treat my rheumatoid arthritis and psoriatic arthritis. Prior to use, I only had some joint pain and psoriasis. However, since taking the drug, I have such severe leg pain that I can't stand or walk without being in agony. Additionally, the psoriasis has not improved at all. The side effects of this medication are very scary and concerning!
2Patient Review
1/24/2018
Sulfasalazine for Psoriasis associated with Arthritis
I started with a lower dosage and worked my way up, as recommended. However, I haven't seen any improvement in my symptoms after about two months of use.
1.7Patient Review
10/23/2021
Sulfasalazine for Rheumatoid Arthritis
I had a really terrible experience while taking this medication. I woke up with a headache, pain in all my joints, and my eyes felt grainy and sandy. My doctor said to cut the pills into quarters and start at a lower dose, but I read that you shouldn't cut the pills. I don't know what to do now.
1Patient Review
3/29/2021
Sulfasalazine for Crohn's Disease
Do not bother with this medication. It did nothing to help my Crohn's Disease and the side effects were debilitating.
1Patient Review
2/1/2018
Sulfasalazine for Rheumatoid Arthritis
This drug is absolutely terrible. After experiencing side effects from plaquenil and Arava, my doctor said to try this awful medicine. I took it for 2 months at 1,000 mg/day. I had debilitating migraines the entire time. One morning I woke up feeling like I was having a heart attack. I couldn't breathe and my chest was tight. I had to go to the hospital by ambulance. Now they believe I have liver damage. Think twice before you swallow this poison!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sulfasalazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is sulfasalazine a steroid drug?

"Sulfasalazine (Azulfidine) is not a steroid, but is actually a "steroid-sparing" medication. This means that it helps to manage your condition and symptoms with a lower dose of corticosteroids."

Answered by AI

What are the long term effects of taking sulfasalazine?

"*The most common side-effects of penicillamine were dyspepsia, nausea, and abdominal discomfort, although rashes and macrocytosis also occurred in a small number of patients. Eighteen of the 21 patients treated with penicillamine showed improvement after nine months, although there was some deterioration noted in some patients after one year."

Answered by AI

What does sulfasalazine do to your body?

"Sulfasalazine works to decrease inflammation in the colon and throughout the body by inhibiting the formation of a chemical known as prostaglandins. Prostaglandins have several important functions in the body, one of which is control of pain and inflammation."

Answered by AI

Does sulfasalazine have side effects?

"This is not harmful.

You may experience stomach upset, nausea, vomiting, loss of appetite, headache, dizziness, or unusual tiredness. If you experience any of these effects, notify your doctor or pharmacist. This medication may cause your skin and urine to turn orange-yellow. This is not harmful."

Answered by AI

Clinical Trials for Sulfasalazine

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Our Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What We Think: We believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What We're Doing: We will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing we'll look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. We'll also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: We've already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. We've also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, we need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of Johns Hopkins University School of Medicine in Baltimore, United States.

N-Acetylglucosamine for Crohn's Disease

13 - 80
All Sexes
Baltimore, MD
This study is a clinical trial of oral N-acetylglucosamine (GlcNAc) in patients with Crohn's disease (CD). This study includes two study groups divided by gene variation in a transporter protein that regulates manganese levels. This genetic variant increases the risk of Crohn's disease (especially involving the ileum) and is carried by approximately 10% of individuals with Crohn's disease. This genetic variant lowers manganese levels, and manganese is important in a cellular process called glycosylation, therefore, glycosylation is changed. Glycosylation in the gut controls the barrier function, interactions with the bugs in the gut, and immune function - all important in Crohn's disease. In this study, the investigators will test if this problem with glycosylation can be targeted by giving GlcNAc. GlcNAc is a key ingredient for glycosylation, and it is currently marketed as a dietary supplement in the United States.
Phase 2
Waitlist Available
Johns Hopkins University School of MedicineJoanna Melia, MD
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Have you considered Sulfasalazine clinical trials? We made a collection of clinical trials featuring Sulfasalazine, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of Precision Clinical Research-Site Number: 8400059 in Coral Springs, United States.

Duvakitug for Crohn's Disease

16 - 80
All Sexes
Coral Springs, FL
This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-week Pivotal Maintenance Sub-Study * 240-week Open-Label Extension (OLE) Sub-Study * 45-day Follow-Up visit Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit. The treatment duration may be up to 280 weeks including: * 40 weeks in the Pivotal Maintenance Sub-Study * 240 weeks in OLE Sub-Study The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study
Phase 3
Recruiting
Precision Clinical Research-Site Number: 8400059 (+2 Sites)Sanofi
Image of Precision Clinical Research-Site Number: 8400059 in Coral Springs, United States.

Duvakitug for Crohn's Disease

16 - 80
All Sexes
Coral Springs, FL
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 weeks with: * Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance Study (EFC18327). The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled study visits for participants who continue to the Pivotal Maintenance Study (EFC18327) will be up to 8 (Sub-Study 1 and Sub-Study 2) and up to 15 for participants who enroll in Sub-Study 3.
Phase 3
Recruiting
Precision Clinical Research-Site Number: 8400059 (+19 Sites)Sanofi
Have you considered Sulfasalazine clinical trials? We made a collection of clinical trials featuring Sulfasalazine, we think they might fit your search criteria.Go to Trials
Image of UMASS medical center in Worcester, United States.

Cranberry for Crohn's Disease

18 - 65
All Sexes
Worcester, MA
This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research suggests that cranberry compounds may help support beneficial gut bacteria. In this study, adults with Crohn's disease will be randomly assigned to one of two groups: one group will receive a cranberry supplement to take once daily for 10 weeks, and the other group will receive a placebo (a supplement with no active ingredients). All participants will be asked to complete online questionnaires and collect samples of their blood, urine, and stool at four time points over a total of 15 weeks. These samples will help researchers understand how the cranberry supplement affects the gut microbiome, inflammation, and overall health. Participation is voluntary, and participants can withdraw from the study at any time. The results of this study may help identify new diet-based approaches to improve gut health in individuals with Crohn's disease.
Phase < 1
Recruiting
UMASS medical centerAna Maldonado-Contreras, PhD
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesHubert LimSecondWave Systems Inc.
Have you considered Sulfasalazine clinical trials? We made a collection of clinical trials featuring Sulfasalazine, we think they might fit your search criteria.Go to Trials